Block & Leviton is investigating whether Ocular Therapeutix misled investors about the design of SOL-R, a pivotal clinical trial for its investigational retinal treatment. In an August 3, 2026 release, the company told investors that the trial's Week 56 primary endpoint "remains unchanged." On November 9, 2026, however, Ocular disclosed that it had moved the primary endpoint up to Week 40. It also acknowledged that the process leading to that change had begun in May 2026, months before the August statement. The same release revealed that about 20% of otherwise eligible patients were being excluded from the trial for early persistent retinal fluid and fluid variability, and also reported third-quarter results below expectations, and the company's stock fell about 6.5%.
You may be able to recover your losses in Ocular Therapeutix stock.
Our attorneys have recovered billions of dollars for defrauded investors. Submit your details for a free, no-obligation case evaluation.